Magic mushroom compound tested for Long-Term grief
NCT ID NCT06724289
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial at the University of Virginia is testing whether psilocybin (the active ingredient in magic mushrooms) can help people with prolonged grief disorder. Twelve adults aged 18-65 with complicated grief will receive a single 25 mg dose of psilocybin along with therapy. The main goal is to see if such a study is feasible, while also tracking changes in grief symptoms and brain activity using fMRI.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- psilocybin
- What this could lead to
- If this early trial shows promise, it could point toward a new therapy option for people struggling with prolonged grief.
- What could go wrong
- This is a very small, early-phase study with only 12 people, so results may not apply broadly. It focuses on feasibility, not proof of effectiveness.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROLONGED GRIEF DISORDER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
University of Virginia
RECRUITINGCharlottesville, Virginia, 22903, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.